Biomarker predicts outcome for prostate cancer:
This article was originally published in Clinica
Executive Summary
The biomarker Ki-67 has emerged as a strong predictor of death from prostate cancer following radiotherapy, according to what is claimed to be the largest known study of its type. Ki-67 is involved in tumour proliferation. A team from the Fox Chase Cancer Center in Salt Lake City, Utah, performed immunohistochemical staining for Ki-67 on tissue samples from 537 patients who has undergone radiation therapy. It found that the higher the amount of Ki-67, the greater the risk the cancer would spread. The findings were reported at the this month's American Society for Therapeutic Radiology and Oncology meeting in Salt Lake City.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.